Growth of breast cancers is often dependent on ovarian steroid hormones making the tumors responsive to antagonists of hormone receptors. However, eventually the tumors become hormone independent, raising the need to identify downstream targets for the inhibition of tumor growth. One possibility is to focus on the signaling mechanisms used by ovarian steroid hormones to induce breast cancer cell proliferation. Here we report that the mitogen-and stress-activated kinase 1 (MSK1) could be a potential druggable target. Using the breast cancer cell line T47D, we show that estrogens (E2) and progestins activate MSK1, which forms a complex with the corresponding hormone receptor. Inhibition of MSK1 activity with H89 or its depletion by MSK1 short hairpin RNAs (shRNAs) specifically abrogates cell proliferation in response to E2 or progestins without affecting seruminduced cell proliferation. MSK1 activity is required for the transition from the G1-to the S-phase of the cell cycle and inhibition of MSK1 compromises both estradiol-and progestin-dependent induction of cell cycle genes. ChIP-seq experiments identified binding of MSK1 to progesterone receptor-binding sites associated with hormone-responsive genes. MSK1 recruitment to epigenetically defined enhancer regions supports the need of MSK1 as a chromatin remodeler in hormone-dependent regulation of gene transcription. In agreement with this interpretation, expression of a histone H3 mutated at S10 eliminates the hormonal effect on cell proliferation and on induction of relevant target genes. Finally, we show that E2-or progestin-dependent growth of T47D cells xenografted in immunodefficient mice is inhibited by depletion of MSK1, indicating that our findings are not restricted to cultured cells, and that MSK1 plays an important role for hormone-dependent breast cancer growth in a more physiological context.
INTRODUCTION
The steroid hormones estrogens (E2) and progesterone (Pg) regulate a wide range of physiological functions. In the mammary gland, E2 enhances development and promotes ductal formation and branching. 1 Pg induces formation of lobular-alveolar structures preparing the gland for milk secretion. 2 In breast cancer cells expressing the corresponding receptors, these hormones exert a proliferative effect 3 and clinical data support that they promote breast cancer development. 4 An increase in the expression of the E2 receptor alpha (ERa) and the progesterone receptor (PR) has been identified at early stages of the tumorigenic process in breast tissue. 5, 6 Approximately 75% of breast tumors are ERa þ , and 60% of them also PR þ . 7 ERa þ / PR þ tumors are more likely to respond to hormonal therapy, 8 although at later stages of progression many of them become hormone-independent, showing a deregulation of mitogenic signaling pathways. E2-and Pg-dependent regulation of gene expression in breast cancer cells is predominantly mediated by ERa and PR. 10 Upon hormone binding, the receptors undergo homodimerization and binding to their cognate DNA sequences followed by recruitment of transcriptional co-activators and the RNA polymerase II. 11 ERa and PR also regulate transcription via protein-protein interactions with transcription factors such as activating protein-1, Sp1, 12 GATA-1 13 or NF-kB. 14 Moreover, hormones activate rapid signaling through binding to a small proportion of their receptors anchored to cell membrane. 15 In ERa þ /PR þ cells, the two receptors can form a complex, which becomes activated by hormone. 15, 16 Upon hormone binding, the receptors activate c-Src, thePI3K/Akt and the MAPK/ERK pathways. 15 Pg-mediated signaling through the MAPK/ERK pathway leads to activation of its downstream effector, the mitogen and stress-activated kinase 1 (MSK1), and formation of a PR/ERK/MSK1 complex. 17 This complex is recruited to the MMTV promoter, where MSK1 phosphorylates histone H3 at serine 10 (ref. 17) , facilitating HP1g-containing repressive complex displacement, and recruitment of 14-3-3 phosphoserine adaptor, chromatin remodeler factors and RNA Polymerase II. 17 Under stress conditions, signaling through the SAPK2/p38 pathway also results in MSK1 activation and phosphorylation of H3S10 over immediate-early gene promoters. 18 In this context, the transcription factors cAMP response-element-binding protein, 19 NF-kB and ATF1 have been described as MSK1 substrates. 20 Considering the requirement of MSK1 for the induction of the MMTV promoter 17 and the broad subset of ER-and PR-target genes considered as positive regulators of cell proliferation, 21 we investigated the role of MSK1 in the proliferative response of 1 Gene Regulation, Stem Cells and Cancer, Centre de Regulació Genó mica (CRG), Barcelona, Spain; breast cancer cells to E2 and Pg. This work reports that MSK1 is required for both S-phase entry of dormant breast cancer cells and induction of cell cycle genes in response to these hormones. In an attempt to find mechanisms by which MSK1 regulates gene expression, we describe progestin-dependent MSK1 recruitment to DNA and its coincidence with PR occupancy. In addition, we show that a loss-of-function mutation over the MSK1 target residue histone H3 S10 precludes hormone dependent cell proliferation and activation of relevant target genes. Finally, we demonstrate that breast cancer cells depleted of MSK1 xenografted in mice are less effective in generating tumors in response to E2 or Pg, suggesting that MSK1 constitutes a potential therapeutic target to control hormone-dependent proliferation of breast cancer cells.
RESULTS
17b-estradiol and progestin promote MSK1 activation and interaction with hormone receptors. In breast cancer cells, E2-ERa interaction promotes signaling through the MAPK pathway. Ligand-activated ERa interacts with the SH2 domain of c-Src activating this pathway. 22 Pg also signals through MAPK upon interaction with cell membrane-attached PR, in complex with ERa, via two ER-interacting domains present in its N-terminal half. 15 In this way, Pg binding to PR promotes activation of unliganded ERa, which in turn activates c-Src. In cells lacking ERa, binding of Pg induces PR-c-Src contact via a lysine cluster within the s-Src SH3 domain, leading to ERK activation. 15, 23 Then, active ERK phosphorylates the PR at S294 (ref. 17) . We previously showed that the ERK target MSK1 is activated by progestin (R5020) in T47D cells, and forms a ternary complex with PR and ERK 17 (Supplementary Figure S1 ). Here we show that E2 also promotes rapid activation of MSK1 (Figure 1a , top panel), which interacts with ER ( Figure 1a, bottom panel) .
Inhibition of MSK1 abrogates E2 and progestin-induced breast cancer cell proliferation but not proliferation in response to serum E2's and R5020's capacity to promote cell proliferation through MAPK pathway-mediated signaling had been described in breast cancer cells. 24, 22 In this context, a role for MSK1 is suggested by the effects of the MSK1 inhibitor H89, 25 which reduced E2 and R5020-induced cell proliferation in the T47D breast cancer cell line (Figure 1b) , as well as in the ER þ /PR þ breast cancer cell line MCF-7 (Supplementary Figure S2) . Because H89 also inhibits the MSK1-related isoform MSK2 and the protein kinase A, 26 we knocked down MSK1 expression in T47D cells by using shRNAs (Figure 1c ) without affecting either MSK2 (Supplementary Figure S3) , or ERa or PR expression (Figure 1d ). Depletion of MSK1 also impaired E2 and R5020-induced cell proliferation in a similar fashion to H89 (Figure 1b) . To assess whether the effect of MSK1 inhibition was also observed in response to other mitogenic stimuli, we studied the influence of H89 on the cell response to 10% fetal bovine serum. Interestingly, inhibition of MSK1 did not affect serum-induced cell proliferation (Figure 1e ), indicating that MSK1 activity is required for the proliferative response of T47D cells to E2 or progestins but not to serum. Figure S5) , at the G 1-phase. Similar results were observed when we quantified the percentage of cells reaching the S-phase in response to E2 and Pg in T47D cells depleted of MSK1 (Figure 2b ), indicating that MSK1 activity is required for the hormone-induced transition from G 1 to S cellcycle phase.
MSK1 activity regulates induction of cell cycle genes in response to progestin and 17b-estradiol As MSK1 is necessary to promote E2-and Pg-mediated cell cycle progression, we explored whether it participates in the hormonemediated regulation of cell cycle genes. Expression microarrays were performed using T47D cells pretreated or not with H89 and subjected to hormone stimulation. R5020 upregulated 1712 genes and downregulated 1447 genes, while E2 induced 577 genes and repressed 555 genes. The inhibitor H89 impaired regulation of 22% and 22.5% of the progestin-induced and repressed genes, respectively. Similarly, 49% and 29.5%, respectively, of E2-induced and repressed genes were affected by H89 (Figure 3a) . Overrepresentation of biological functions among genes whose hormone regulation was affected by H89 was determined by using the 'Core Analysis' function of IPA (Ingenuity System) (P-valueo0.05). The functions cell death, tumor morphology, cell cycle, growth, proliferation and cancer were overrepresented among progestin-regulated genes affected by H89 (see Table 1 ), whereas cell growth and proliferation, cancer, cell cycle, cellular movements, DNA replication, recombination and repair genes affected by H89 were subjected to validation using MSK1 shRNAs. Among progestin-regulated genes, we validated cyclin E2 (Ccne2), cyclin D1 (Ccnd1), epidermal growth factor (Egf) and its receptor (Egfr), Dusp-1, HexokinaseII (Hk2), which catalyzes the first step of the glycolytic pathway, 27 the chloride channel Clic6 and uronyl-2-sulfotransferase (Ust) (Figure 3b ). Among the E2-regulated genes, we validated connective tissue growth factorlike Wisp2, the Sgk3 kinase, Hexokinase II (Hk2), Fgd3, Tff1, hydroxysteroid (11-beta) dehydrogenase 2 (Hsd11B2), dualspecificity A-kinase-anchoring protein 1 (Akap1) and annexin A1 (Anxa1) (Figure 3c ). Inhibition of MSK1 expression reproduced the H89-mediated impairment in hormone-mediated regulation of these genes ( Figure 3c ).
MSK1 is recruited by PR to chromatin
The significance of MSK1 in gene regulation and its hormonedependent interaction with PR prompted us to explore whether MSK1 is recruited to PR-binding sites in chromatin. We performed ChIP-seq experiments in control and T47D cells treated with R5020 for 2 and 5 min, using antibodies for MSK1 and the Illumina genome analyzer. Sequence reads were aligned to human genome hg19 assembly using the Bowtie program. Peaks were defined with the MACS algorithm and only hormone-dependent peaks with a P-value o1E À 11 were considered according to their reproducibility (Supplementary Figure S6) . We found 4484 progestin-dependent MSK1 peaks after 2 min of R5020 treatment and 6678 after 5 min. Interestingly, progestin promoted MSK1 recruitment at coding exons ( Figure 4a ). In addition, we also analyzed MSK1 occupancy at enhancers by considering the 28 R5020 promoted an increase in MSK1 occupancy at H3K4me1-containing regions ( Figure 4b ). When considering progestin-dependent MSK1 peaks, we found that 87.3 and 70% of the MSK1 peaks at 2 and 5 min of R5020 induction, respectively, overlapped with the H3K4me1 (Figure 4c ), suggesting MSK1 participation in the regulation of hormonedependent gene expression by recruitment at enhancers.
We next examined whether regions showing progestindependent MSK1 recruitment coincided with PR-binding sites obtained in previous work. 29 Analysis of the intensity profiles before and after progestin treatment showed MSK1 accumulation around the center of PR-binding regions, indicating significant overlapping between hormone-dependent MSK1 and PR binding (Figure 4d , upper plot). Absence of overlapping was observed when random sequences were considered (Figure 4b , lower plot). It is observed that 50.26% of hormone-dependent MSK1 peaks at 2 min of R5020 stimulation and 22.68% at 5 min showed coincidence with PRbs ( Figure 4e ). These results suggest that the formation of the PR-MSK1 complex at the MMTV promoter in response to progestin 17 can be extended to a genome-wide level. In an attempt to determine whether there is a relationship between progestin-dependent MSK1 occupancy and gene regulation, microarray and ChIP-seq data were combined. Three groups of genes classified as up-, down-and not-regulated by R5020 were analyzed for the presence of hormone-dependent MSK1 occupancy within a window covering from À 20 kb upstream the transcription start site to þ 20 kb downstream the transcription termination site. Whereas 21.91% and 16.29% of the MSK1 binding sites at 2 and 5 min, respectively, surrounded progestin-regulated genes, only 2.9% and 3% of MSK1-binding sites were surrounding hormone-independent genes (Figure 4f ).
We previously demonstrated MSK1 participation in progestininduced chromatin remodeling at the nucleosome B of MMTV promoter as a mechanism to induce gene transcription. 18 In this model, MSK1-mediated phosphorylation of histone H3S10 promotes displacement of an HP1g-containing repressive complex and anchoring of the NURF complex required for histone H1 displacement. 30 To determine whether MSK1 mediates genome-wide progestin-dependent chromatin remodeling, we used nucleosome occupancy data mapped in T47D to classify all PRbs into those with high and low progestin-dependent nucleosome remodeling index. 29 PRbs with high nucleosome remodeling index exhibit preferential accumulation of MSK1 reads in response to hormone (P-value o0.05) (Supplementary Table 1) , supporting a role for MSK1 in mediating progestin-dependent chromatin remodeling and transcription regulation.
Mutation of histone H3 at S10 impairs progestin-mediated breast cancer cell proliferation and gene induction To confirm the physiological relevance of H3S10 phosphorylation, we generated T47D cells expressing flagged wild-type histone H3 or the S10A mutant (Figure 5a , left panels). The E2 and R5020-mediated proliferative response of these cells was evaluated. The corresponding P-value for each function is represented according to whether it associates with genes up-or downregulated in response to each hormone. Only those genes whose hormone-mediated regulation (FC ± 1.40, P-valueo0.05) was impaired by at least twofolds in the presence of H89 and present in both array platforms (Sureprint G3 Human gene expression array 8 Â 60K for treatment with 17b-estradiol and Agilent Human GE 4 Â 44K for treatment with R5020) were considered. The ingenuity pathways analysis tool was used to determine biological functions overrepresented among hormone-regulated genes affected by H89 (P-value considered for significance: o0.05). Functions associated with a given regulatory pattern (up/down) with a P-value 40.05 were not considered to be significant (NS).
Role of MSK1 in breast cancer progression D Reyes et al
To test the contribution of H3S10 phosphorylation in the regulation of gene transcription, we analyzed by RT-qPCR the mRNA levels of cyclin D1, cyclin E2, Dusp-1, Egf, Egf Receptor, and Clic6 before and after progestin stimulation. Except for Egfr and Hk2, progestin-dependent induction of those genes was affected in cells expressing the H3S10A mutant (Figure 5c ).
MSK1 depletion impairs progestin and E2-induced tumor growth in mice xenografts
We next tested whether the dependence of hormone-induced cell proliferation on MSK1 activity was also observed in the organismal context. T47D cells expressing the chimera Renilla luciferase/red fluorescent protein (RFP) and transduced with either a control shRNA or an shRNA targeting MSK1 expression were generated. Cells were intramuscularly implanted in severe combined immunodeficient mice for in vivo tumor growth monitoring by non-invasive bioluminescent imaging. Subcutaneous administration of Pg or 17b-estradiol pellets to mice promoted significantly higher tumor growth in tumors formed by T47D cells expressing the control shRNA (Figure 6a , left leg) compared with tumors formed by cells depleted of MSK1 (Figure 6a, right leg) , which exhibited low levels of this protein as determined by western blot (Supplementary Figure S7) . A quantitative evaluation in the average growth of both types of tumors from seven independent animals is shown in Figure 6b (P-value o0.05 for both hormones). Histological images of the tumors showed that cells depleted of MSK1 generated tumors with a lower density of tumoral cells than the control cells (Supplementary Figure S8) .
DISCUSSION
Activation of the MAPK pathway in response to mitogens regulates a plethora of physiological functions depending on the cell's identity and signals impinging on the cell. Therefore, the same signaling pathway leads to distinct responses in different contexts. The ubiquitously expressed kinase MSK1 is activated by p38 in response to stress stimuli and by ERK1/2 in response to mitogens. 19 As a downstream effector of ERK1/2, MSK1 regulates chromatin remodeling by phosphorylation of histone H3S10 (ref. 17) . However, other kinases such as protein kinase A, RSK2, PIM1, IKKa or Aurora kinase B also phosphorylate histone H3S10. This modification regulates two opposing functions: In mitosis, it appears in the early G 2-phase within the pericentromeric heterochromatin as a result of Aurora B kinase activity 31 facilitating HP1a displacement, 32 whereas in interphase, it promotes transcription initiation as (Figure 3c ) was also affected in cells expressing the H3S10A mutant. RNA extracts coming from T47D-MTVL cells expressing either the H3wt (black columns) or the H3S10A mutant (white columns) were extracted before and 6 h after stimulation with R5020 (6 h). The columns indicate the hormone-induced fold change obtained after dividing the RNA content at 6h by the value of untreated cells. The fold change of mRNA levels after hormonal treatment was normalized by the housekeeping gene GAPDH.
Role of MSK1 in breast cancer progression D Reyes et al a result of RSK2 33 and MSK1/2 activity 34 over regulatory regions of genes responsive to a given stimulus. Progestin-dependent H3S10ph upon MSK1-PR interaction mediates chromatin remodeling favoring displacement of an HP1g-containing repressive complex and promoting MMTV promoter activation. 35 Here, we report that MSK1 also interacts with ER in response to estradiol and is needed for E2-dependent breast cancer cell proliferation.
As inhibition of Aurora B would lead to a general inhibition of cell proliferation due to the blockage of mitosis, a lack of MSK1 activity blocks selectively steroid hormone-induced cell proliferation without affecting proliferation in response to other stimuli.
Here we show that MSK1 is required for the G 1 /S-phase transition. In response to mitogens, ERK-mediated signaling is necessary for reaching the S-phase. ERK activity promotes cyclin D1 induction, 36 which accumulates during G 1-phase and assembles with cyclin-dependent kinases 4 and 6 (Cdk4/6), resulting in phosphorylation of retinoblastoma and its dissociation from E2F transcription factor and transcription of genes required for DNA replication. 37 Cyclin E2 also contributes in the G 1 /S-phase transition by interacting with Cdk2 and enhancing phosphorylation of Rb. 38 Since MSK1 signals downstream ERK 19 and progestin-mediated upregulation of cyclin D1 and cyclin E2 is blocked by H89 and MSK1 The key role of MSK1 in progestin-induced cell proliferation via its effect on cyclins is not the only aspect of breast cancer growth influenced by this kinase. Hormonal regulation of genes involved in cell cycle, growth, proliferation and cancer also depends on MSK1 activity. Interestingly, a lack of MSK1 also affects estradiolmediated induction of genes related to cellular movement and cell-to-cell interaction. Further studies are required to elucidate whether MSK1 could participate in tumor invasiveness or its capacity to metastasize.
The mechanisms by which MSK1 regulates gene transcription can be direct or indirect. Our work focuses on the direct mechanisms mediated by MSK1-DNA interaction. ChIP-seq experiments revealed that MSK1 is recruited to genomic sequences in response to progestin and that active PR targets the kinase to PRbs. This behavior is reminiscent of the recruitment to the immediateearly genes Jun, Cox-2 and Fosl1, which is mediated by MSK1's interaction with the transcription factors Elk1, NF-kB and C/EBPb in response to 12-O tetradecanoylphormbol-13-acetate (TPA). 39 Direct involvement of MSK1 in MMTV promoter activation upon progestin stimulation has been well characterized. Upon recruitment to DNA, MSK1 phosphorylates histone H3S10, leading to displacement of HP1g-containing repressive complex. 17 This facilitates access of the ASCOM complex containing MLL2/3 methyltrasferases that trimethylate H3 at K4 anchoring NURF and favoring recruitment of PARP1/CDK2/CyclinA complexes.
30 CDK2 then phosphorylates histone H1 and activates PARP1, contributing to histone H1 displacement. 40 In a second remodeling cycle, H3S10 phosphorylation, along with the PCAF, mediates H3K14 acetylation and favors the anchoring of the BAF complex, which displaces histone H2A/H2B dimmer, enabling access of NF1, PR-BAF complexes and the formation of the transcription preinitiation complex. 30 We cannot exclude that, in addition to these direct effects, MSK1 could regulate gene expression via indirect mechanisms including phosphorylation of the transcription factors cAMP response-element-binding protein , ATF1 and NF-kB. 19, 41 We conclude that MSK1 activity is essential to selectively promote steroid-hormone induced breast cancer cell proliferation, and therefore represents a possible therapeutic target for hormone-responsive breast tumors. This idea is supported by the results of tumor growth in mice xenografts, showing that E2 or Pg-dependent growth requires MSK1. Moreover, the existence of either single or double knockout mice for MSK1/2 42, 43 indicates that a lack of this kinase does not compromise viability.
As MSK1 prevents cell proliferation in response to hormone but only affects around 20% of the hormone-regulated genes, selective inhibition of this kinase should modulate growth of hormone-dependent breast tumors without affecting other hormonal responses, which are blocked by the present treatment with hormone receptor antagonists, such as tamoxifen. Moreover, it is possible that when tumors become hormone-independent and insensitive to receptor antagonists, they still maintain their dependence on activation of the ERK/MSK1 pathway and therefore could still respond to inhibition of MSK1 activity with a decrease in the their growth rate.
MATERIALS AND METHODS
Cell culture and hormone treatments T47D and MCF-7 cells were cultured in RPMI 1640 or DMEM medium, respectively, supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 1C in a 5% CO 2 -containing atmosphere. Cells were seeded at 25% confluence and cultured in phenol red-free RMPI or DMEM medium with 10% dextran-coated charcoal-treated FBS (DCC/FBS). Forty-eight hours later, the medium was replaced by serum-depleted medium. Sixteen hours later, cells were incubated at 37 1C, with R5020 or estradiol (10 nM) for the indicated times.
Lentiviral particle production
Empty pLKO.1-puro and the pLKO.1-puro lentiviral MISSION shRNA for human MSK1 (clone ID: NM_004755.x-336s1c1, Sigma-Aldrich, St Louis, MO, USA) were transducted to knockdown MSK1 in T47D cells. Production of viral particles was performed as previously described in Sancho et al. 44 using the pCMVDR8.91 (15 mg), the pVSVG (5 mg) and the empty pLKO.1-puro or the pLKO.1-puro construct, containing the MSK1 shRNA (10 mg).
For the production of T47D cells expressing the Renilla luciferase-RFP protein, infection was performed as described above using the lentiviral transfer vector DNA CMV:hRLuc:RFP:ttk (15 mg) and the pMD-G-VSV-G and the pCMV DR8.2 (10 mg) constructs. The highest 11% RFP-expressing cells were selected by FACS.
Immunoblotting, co-immunoprecipitation assay and immunofluorescence
Western blot experiments were performed as described in Subtil-Rodriguez et al. After treatment with 10 nM of 17-b estradiol for 5 min, we performed coimmunoprecipitation as described in Vincent et al. 30 using the anti-ERaand the anti-MSK1 antibodies mentioned above.
Immunofluorescence was performed as described in Subtil-Rodriguez et al. 45 with T47D cells expressing the H3wt or the H3S10A mutant. To detect the FLAG, we used the mouse monoclonal anti-FLAG M2 antibody, Sigma-Aldrich (F1804) and the Alexa Fluor 488-conjugated goat antimouse immunoglobulin G (IgG; A11029, Invitrogen, Carlsbad, CA, USA).
Stable expression of FLAG-tagged histone H3wt and S10A mutant
The pCMV-Tag2A containing the full-length human histone H3.1 cloned between the BamHI-HindIII sites was provided by Dr Di Croce's lab. Histone H3S10A mutation was created by site-directed mutagenesis with QuikChange II Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) using the forward oligonucleotide 5 0 -CAAACTGCTCGCAAGGCCACGGGTGG-GAAAG-3 0 and the reverse 5 0 -CTTTCCCACCCGTGGCCTTGCGAGCAGTTTG-3 0 . Generation of the H3.1-expressing constructs was performed in two steps. H1.3wt and S10A mutant were cloned from the pCMV-Tag2A to the pCMV3Tag-6 vector (Agilent), using the BamHI-HindIII sites. Then, the NotI-ClaI sites were used to clone the 3X-FLAG H3.1wt and S10A, from the pCMV3Tag-6 to the retroviral vector pLPCX. Retroviral vectors were transduced in T47D cells as described above using the GP2-293 packaging cell line.
Quantification of BrdU incorporation and cell cycle analysis
Cells were cultured overnight in serum-depleted medium before hormone induction. R5020, E2 (10 nM) or serum (10%) was added to the cells after 1 h of pre-treatment with H89 at 15 mM (Alexis, San Diego, CA, USA) when indicated. BrdU (Roche, Basel, Switzerland) (10 mM) was added 13 h after stimulation and cells were incubated for 2 h at 37 1C. After labeling, cells were harvested, washed once with PBS and fixed in 70% ethanol. Cells were incubated in DNA denaturing solution (2N HCl, 0.5% BSA) for 10 min and washed with PBS. Detection of incorporated BrdU was performed using the anti-bromodeoxyuridine antibody (BD ref. 555627) and the goat anti-mouse FITC-conjugated antibody (DAKO ref. F0479, DAKO, Santa Clara, CA, USA). Samples were analyzed using a FACSCalibur machine (Becton Dickinson, Franklin Lakes, NJ, USA) and CellQuest analysis software (CellQuest, Rockefeller University, New York, NY, USA). Cells were washed with PBS, fixed in 70% ethanol and stained with analysis solution: 3% ribonuclease A (Sigma) 10 mg/ml, 3% solution A (38 mM sodium citrate, 500 mg/ml propidium iodide) in PBS. Samples were analyzed using a FACSCalibur machine (Becton Dickinson) and CellQuest analysis software.
Cell count assays T47D and MCF-7 cells were seeded at 25% confluence in six-well plates and starved as described above. Cell proliferation was induced by R5020 or estradiol (10 nM). The effects of MSK1 inhibition were assessed by adding H89 (15 mM) to the culture medium. At the induction time, cells were harvested and counted using a Neubauer chamber. Counts were performed every 2 days. Culture medium with the corresponding hormones and inhibitor was replaced every 48 h. Experiments were performed in triplicates. Quantitative ChIP assays and ChIP-Seq analysis
ChIP assays were performed as described in Strutt and Paro 46 using an anti-MSK1 antibody (H-65) Santa Cruz Biotechology (sc-25417). Cells were incubated during 2 or 5 min with R5020 (10 nM). Quantification of ChIP was performed by qPCR using LightCycler (Roche). The fold enrichment of the target sequence in the immunoprecipitated compared with input fractions was calculated as described in Vincent et al. 47 Primers' sequences are available on request.
DNA was subjected to deep sequencing using the solexa genome analyzer (Illumina). Single-ended sequences were trimmed to 36 bp and mapped to the human genome assembly hg19 using Bowtie (http// bowtie-bio.sourceforge.net) an ultrafast short-read mapping program, 48 keeping only tags that mapped uniquely and with no more than two mismatches.
The integrated software MACS was used to detect peaks enriched from background reads. The algorithm was applied by using the sliding window method to count the reads with default settings and a P-value threshold of 1E À 11, to identify differential binding between the two conditions by treating the T0 of the samples as the control. Genome-wide annotations and statistics of protein-DNA interaction patterns from ChIP-seq data were performed with the stand-alone application CEAS (Cis-regulatory element annotation system). Signals from treated and untreated samples were compared using poisson analysis (P-value o0.001).
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Microarrays and data analysis RNA was isolated from T47D cells and treated 6 h with either R5020 or 17b-estradiol (10 nM) alone or in combination with H89 (15 mM). Basal levels of gene expression were considered from untreated or cells pre-treated for 1 h with H89. Hundred nanogramsof RNA was labeled using Low Input Quick Amp Labeling Kit (Agilent 5190-2305) following the manufacturer's instructions. Labeled RNA was hybridized to Agilent SurePrint G3 human gene expression 8 Â 60K (for 17b-estradiol-treated cells) and to Agilent Human GE 4 Â 44K microarray (for R5020-treated cells). Arrays were washed, and scanned on an Agilent G2565CA microarray scanner at 100% PMT and 3 mm resolution. Intensity data were extracted using the Feature Extraction software (Agilent).
Statistical analysis
Raw data were taken from the Feature Extraction output files and corrected for background noise using the normexp method. 49 To assure comparability across samples, we used quantile normalization. Differential expression analysis was carried out on non-control probes with an empirical Bayes approach on linear models. 50 Results were corrected for multiple testing according to the false discovery rate method. All statistical analyses were performed with the Bioconductor project ((http:// www.bioconductor.org/) in the R statistical environment http://cran .r-project.org/); only the probes with a present call were considered for the analysis. The differentially expressed probes were determined by the fold change of expression levels ± 1.40 and P-valueo0.05. Probes were mapped to genes using the nucleotide universal identifier annotation. Analysis of overrepresented pathways among the subset of genes affected by H89 was performed using the ingenuity pathways analysis tool, considering only genes present in both array platforms.
Cell inoculation in mice and bioluminescence imaging
Seven week-old BALB/c homozygous nude nu/nu mice were anesthetized by intraperitoneal injection with a mixture containing 100 mg/kg ketamine (Merial, Duluth, GA, Georgia) and 3.3 mg/kg xylocaine (Henry Schein, Melville, NY, USA). Seven mice received subcutaneous pellets containing 17-b-estradiol (1.7 mg) and other seven received subcutaneous pellets containing Pg (10 mg) from IRA. For cell inoculation, cells were harvested, washed twice with PBS, resuspended (5 Â 10 5 cells in 0.05 ml), mixed with 0.05 ml of matrigel and injected into the left (shRNA) and right (shcontrol) thigh of each mouse. For in vivo bioluminescence imaging, anesthetized mice were intravenously (tail vein) injected with 25 ml of benzyl coelenterazine (hCTZ) (1 mg/ml in 50/50 propileneglycol/ethanol) (Nanolight Technology, Pinetop, AZ, USA) and placed in an IVIS Spectrum in vivo photon-counting device (Caliper Life Sciences, Alameda, CA, USA). Images were taken every 3 days. The bioluminescence imaging was analyzed using Living Image 3.10 software (Caliper Life Sciences).
Histology samples preparation
Tumor samples were fixed in 4% buffered paraformaldehyde, paraffinembedded using standard procedures, cut into 5 mm-slides and routinely processed for hematoxylin-eosin staining.
